Mazdutide studies
90 journal papers mention Mazdutide in the title or abstract. Here are the most cited, the latest, and a few facts about the literature.
Studies range from laboratory work to clinical trials. A paper listed here is not an endorsement and says nothing about whether Mazdutide is safe, effective or approved for any use.
- Papers
- 90
- 55 articles, 35 reviews
- Earliest paper
- 2021
- Most papers in 2026 (44)
- Open access
- 60%
- free to read somewhere
- Reviews
- 39%
- of all papers listed
What kind of studies
Of 58 papers in PubMed that mention Mazdutide in the title or abstract, by the study type PubMed records. Categories overlap, so they do not add up to the total.
- Randomized controlled trials10
- Other clinical trials0
- Meta-analyses and systematic reviews10
- Other reviews27
- Case reports2
- Animal studies only1
- Studies in humans37
Study types are tags assigned by publishers and PubMed indexers; very new papers are often not tagged yet, and a tag is not a quality rating. Retracted papers are excluded. Source: PubMed (NCBI).
Registered clinical studies
Studies on ClinicalTrials.gov that mention Mazdutide in their intervention details. A registration says a study is planned or running, not what it found.
- Registered
- 46
- Completed
- 19
- Ongoing or planned
- 26
- Phase 1
- 13
- Phase 2
- 13
- Phase 3
- 11
- Mazdutide for Reducing Atrial Fibrillation Recurrence After Catheter Ablation in Obese Patients
NCT07897305Not yet recruitingstarted 2026-10-25
- ASCEND-1: Lifestyle Intervention Plus Mazdutide for Weight Management
NCT07517042Recruitingstarted 2026-06-10
- A Study of IBI362 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)
NCT06937749Active, not recruitingPhase 2started 2025-06-20
- Effect of Mazdutide on Coronary Plaque in Patients With Coronary Atherosclerosis and Overweight or Obesity
NCT07657676RecruitingPhase 4started 2026-09-14
- A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
NCT06143956RecruitingPhase 2started 2023-11-17
The five most recently updated studies. See all 46 on ClinicalTrials.gov. Source: ClinicalTrials.gov (U.S. National Library of Medicine). Studies are found by the compound's name, so a few may be about something else.
Papers per year
2021 to 2026, peak 44 papers in a year. The latest year may still be incomplete.
Where it is published
- Diabetes16 papers
- Diabetes Obesity and Metabolism6 papers
- Frontiers in Endocrinology4 papers
- JAMA3 papers
- The Lancet Diabetes & Endocrinology3 papers
The papers
Most citedName in the title
- Efficacy and safety of Mazdutide on weight loss among diabetic and non-diabetic patients: a systematic review and meta-analysis of randomized controlled trials
David Lubasi Nalisa, Nelson Cuboia, Eman Ali Dyab et al. · Frontiers in Endocrinology · 2024
Meta-analysisOpen access · CC BY30 citationsRead the open copy →
- Efficacy and Safety of Mazdutide in Managing Overweight and Obesity Among Non‐Diabetic Adults: A Meta‐Analysis of Randomised Controlled Trials
Muhammad Hussain Azam, Muhammad Hussain Azam, Khair‐un‐Nisa Azam et al. · Diabetes Obesity and Metabolism · 2026
Meta-analysis3 citations
- Mazdutide Versus Dulaglutide for Weight Loss and Diabetes Management: Meta-Analysis of Randomized Clinical Trials
Hazem Ayesh, Suhail K. Ayesh, Kevin Dean Niswender · American Journal of Therapeutics · 2024
Meta-analysis3 citations
- Efficacy and Safety of the Dual Glucagon‐Like Peptide‐1 and Glucagon Receptor Agonist Mazdutide in Predominantly Chinese Adults With Obesity and/or Type 2 Diabetes: A Systematic Review and Meta‐Analysis
Abul B. M. Kamrul-Hasan, Subhankar Chatterjee, Hamid Ashraf et al. · Diabetes Obesity and Metabolism · 2026
Meta-analysisOpen access1 citationsRead the open copy →
- Patent landscape and therapeutic evolution of mazdutide: a dual GLP-1/Glucagon receptor agonist for obesity and type 2 diabetes
Mohammed Abdul Fasi · Expert Opinion on Therapeutic Patents · 2026
Review1 citations
- Comparison of Mazdutide and Dulaglutide for Type 2 Diabetes: a GRADE assessed systematic review and meta-analysis of randomized controlled trials
Ahmad Hassan, Qurrat Ul Ain Farooq, FNU Parwesh et al. · F1000Research · 2026
ReviewOpen access · CC BYRead the open copy →
- Mazdutide and the metabolic treatment revolution
Xianyu Li, Bibo Shao, Min Ruan et al. · Trends Open · 2026
ReviewOpen access · CC BYRead the open copy →
- Efficacy and Safety of Mazdutide for Type 2 Diabetes: a GRADE assessed systematic review and meta-analysis of randomized controlled trials
Affaf Mahmood, Noor Us Sehar, Aimen Farooq et al. · F1000Research · 2026
ReviewOpen access · CC BYRead the open copy →
- Efficacy and safety of mazdutide vs. dulaglutide in adults with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials
Muhammad Hassan, Muhammad Hussain, Saifullah Khan et al. · Diabetology & Metabolic Syndrome · 2026
ReviewOpen access · CC BYRead the open copy →
LatestName in title or abstract
- EMERGING PHARMACOLOGICAL STRATEGIES IN OBESITY: FROM GLP-1 AGONISTS THROUGH TRIPLE INCRETIN THERAPY TO AMYLIN ANALOGS – NARRATIVE REVIEW
Dagmara Laufer, Olga Klimczak, Filip Chodań et al. · Archiv Euromedica · 2026
ReviewOpen accessRead the open copy →
- The pharmacotherapy for pediatric obesity: insights and challenges from adult weight-loss medications
Zhiyu Chen, Ying Zhou, Gang Li et al. · Journal of Diabetes & Metabolic Disorders · 2026
ReviewOpen accessRead the open copy →
- The Power of Two: Harnessing Dual Glucagon and Incretin Signaling for Treatment of Obesity and Metabolic Dysfunction–Associated Steatohepatitis—A Narrative Review with a Translational Focus
Jamy D. Ard, Jaime P. Almandoz · Obesity Reviews · 2026
ReviewOpen accessRead the open copy →
- Effects of Incretin-Based Pharmacotherapies on Lean Body Mass in Adults With Overweight, Obesity, or Type 2 Diabetes: A Systematic Review With Prespecified Network Meta-Analysis Feasibility Assessment
Zahi M Alhamad, Naif AlShalhoub, Abdulrahman Al-mana et al. · Cureus · 2026
ReviewOpen access · CC BYRead the open copy →
- Efficacy and Safety of Dual GLP ‐1/Glucagon Receptor Agonism in Overweight and Obesity: A Class‐Specific Systematic Review and Meta‐Analysis
Muhammad Maaz Amjad, Muhammad Mustafa Khan, Fatima Sarwar et al. · Diabetes Obesity and Metabolism · 2026
ReviewOpen accessRead the open copy →
- Comparison of Mazdutide and Dulaglutide for Type 2 Diabetes: a GRADE assessed systematic review and meta-analysis of randomized controlled trials
Ahmad Hassan, Qurrat Ul Ain Farooq, FNU Parwesh et al. · F1000Research · 2026
ReviewOpen access · CC BYRead the open copy →
- Mazdutide and the metabolic treatment revolution
Xianyu Li, Bibo Shao, Min Ruan et al. · Trends Open · 2026
ReviewOpen access · CC BYRead the open copy →
- Efficacy and Safety of Mazdutide for Type 2 Diabetes: a GRADE assessed systematic review and meta-analysis of randomized controlled trials
Affaf Mahmood, Noor Us Sehar, Aimen Farooq et al. · F1000Research · 2026
ReviewOpen access · CC BYRead the open copy →
- Comparative efficacy and safety of glucagon-like peptide 1 based drugs for weight loss in adults with overweight or obesity without diabetes: network meta-analysis of randomised controlled trials
Deshi Chen, Bing Ma, Hao Sun et al. · BMJ Medicine · 2026
ReviewOpen access · CC BY-NCRead the open copy →
- Cardiovascular Effects of Glucagon Receptor Signaling Alone and Combined With Glucagon‐Like Peptide‐1 Receptor Signaling in Multiagonists: A Narrative Review With a Translational Focus
Pamela R. Kushner, Erin D. Michos · Journal of the American Heart Association · 2026
ReviewOpen access · CC BY1 citationsRead the open copy →
- Efficacy and safety of mazdutide vs. dulaglutide in adults with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials
Muhammad Hassan, Muhammad Hussain, Saifullah Khan et al. · Diabetology & Metabolic Syndrome · 2026
ReviewOpen access · CC BYRead the open copy →
- Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis
Kailei Nong, Qingyang Shi, Xinran Xie et al. · BMJ · 2026
Systematic reviewOpen access · CC BY-NC10 citationsRead the open copy →
- Efficacy and Safety of the Dual Glucagon‐Like Peptide‐1 and Glucagon Receptor Agonist Mazdutide in Predominantly Chinese Adults With Obesity and/or Type 2 Diabetes: A Systematic Review and Meta‐Analysis
Abul B. M. Kamrul-Hasan, Subhankar Chatterjee, Hamid Ashraf et al. · Diabetes Obesity and Metabolism · 2026
Meta-analysisOpen access1 citationsRead the open copy →
- Beyond weight loss: multisystem benefits of obesity medications
Mesut Savas, Susanne Kuckuck, Mariëtte R. Boon et al. · The Lancet Diabetes & Endocrinology · 2026
Review4 citations
- Obesity pharmacotherapy reimagined: The era of multi-receptor agonists and next-generation metabolic modulators, perspectives and controversies
Ioannis G. Lempesis, Μaria Dalamaga · Metabolism Open · 2026
ReviewOpen access · CC BY8 citationsRead the open copy →
- Patent landscape and therapeutic evolution of mazdutide: a dual GLP-1/Glucagon receptor agonist for obesity and type 2 diabetes
Mohammed Abdul Fasi · Expert Opinion on Therapeutic Patents · 2026
Review1 citations
- Efficacy and Safety of Mazdutide in Managing Overweight and Obesity Among Non‐Diabetic Adults: A Meta‐Analysis of Randomised Controlled Trials
Muhammad Hussain Azam, Muhammad Hussain Azam, Khair‐un‐Nisa Azam et al. · Diabetes Obesity and Metabolism · 2026
Meta-analysis3 citations
- Incretin-Based Dual and Triple Agonists in Overweight or Obese Individuals: A Systematic Review and Meta-Analysis
Zhi Hong Chan, Abdousamad Said Omar, Kieran Gill et al. · Cardiology in Review · 2026
Review1 citations
Each list shows up to 40 papers.See all 90 on OpenAlex. Source: OpenAlex (CC0), journal articles and reviews with a DOI, retractions excluded, refreshed weekly, last 4 Nov 2026, 08:31 UTC. Papers are listed by their metadata only; follow the links to read them. A license shown on an open copy is the license the publisher or repository states for that copy.